Cancer Treatments
Chronic Stress and Obesity May Promote Pancreatic Cancer Growth via CREB Activation, Study Suggests
Key Takeaways Stress and obesity may contribute to pancreatic cancer: Both factors activate biological pathways that may accelerate tumor growth. Women may be more vulnerable: Hormonal differences could heighten stress-related …Metformin and Syrosingopine: Diabetes and Blood Pressure Drugs Show Promise Against Cancer in Early Study
Key Takeaways: A drug pairing of metformin (diabetes medication) and syrosingopine (blood pressure drug) shows potential for starving cancer cells. The combo blocks two critical energy pathways cancer cells …Prostate Cancer MRI Scans May Underestimate Tumor Size: UCLA Study Warns of Treatment Risks
Key Takeaways: Prostate cancer is the second leading cause of cancer death in U.S. men, but early detection boosts survival rates to nearly 100%. Age, family history, and race …Short-Term Rapamycin Treatment May Be Sufficient for Lifespan Extension, Reducing the Need for Lifelong Use
A team of researchers from the Max Planck Institute for Biology of Ageing has revealed that brief exposure to the macrolide drug rapamycin could have similar effects on lifespan …Possible Solution for Cancer Pain Through Electrical Stimulation of the Pituitary Gland
Globally, the prevalence of cancer has risen, with a projected increase in the number of annual cases from 14 million to 32 million in 2032. If detected early, cancer …Vibrating Molecules Can Kill 99% of Cancer Cells Without Hurting Healthy Tissue
Researchers have just developed a promising strategy to combat melanoma, offering a potential new pathway in cancer treatment. This article explores their innovative approach, poised to change the landscape …Durvalumab (Imfinzi) Boosts Survival in Early-Stage Lung Cancer: What Patients Should Know
Key Takeaways: Adding Durvalumab (Imfinzi) to chemotherapy before and after surgery significantly improves outcomes for early-stage non-small cell lung cancer (NSCLC). Patients receiving Durvalumab had a 73% chance of …Immunotherapy Transforms Melanoma Outcomes: French Study Highlights Progress, Challenges, and Key Survival Data
Key Takeaways: Dual immunotherapy (anti-PD-1 + anti-CTLA-4) achieves 77% survival at 6.5 years in metastatic melanoma, compared to 69% with anti-PD-1 alone. Combination therapy boosts efficacy but increases severe …Gene Editing as a Novel Approach in the Treatment of Acute Leukemias
A recent study carried out by a group of researchers from Seattle Children’s Research Institute and the Children’s Hospital of Philadelphia has shed new light on ongoing efforts to …Posts pagination
Gilmore Health News uses cookies to improve your experience and to deliver the best possible browsing experience. For additional details, refer to the Gilmore Health Privacy Policy. By entering our site you are agreeing to our terms! Accept Privacy Policy
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are as essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.